GlassScriptPhysician profile
Elen B Blochin
NPI 1316102999
$783.72
in general payments reported to CMS, 2019-2025
13 companies · $79.99 in 2025
The $79.99 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $214 · 2024: $35.00 · 2025: $79.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $95.26 · Food and Beverage: $19.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $95.26 |
| Food and Beverage | $19.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $178.99 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $125.36 | 2019-2020 | |
| Abbvie INC. | $85.88 | 2019-2020 | |
| Lilly USA, LLC | $73.18 | 2019-2020 | |
| Pfizer INC. | $54.93 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.65 | 2019 | |
| Biofrontera INC. | $50.81 | 2019 | |
| Celgene Corporation | $41.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $40.22 | 2020 | |
| Amgen INC. | $24.08 | 2020 | |
| Almirall LLC | $19.73 | 2024 | Seysara |
| Novartis Pharmaceuticals Corporation | $19.43 | 2019 | |
| Ucb, INC. | $18.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elen Blochin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.